Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Diabetes

Journal Scan / Research · September 07, 2017

PCSK9 Inhibitor Price Reduction Essential for Cost-Effectiveness

JAMA: The Journal of the American Medical Association

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Christopher Cannon MD

JAMA: The Journal of the American Medical Association
Updated Cost-Effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
JAMA 2017 Aug 22;318(8)748-750, DS Kazi, J Penko, PG Coxson, AE Moran, DA Ollendorf, JA Tice, K Bibbins-Domingo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated